Prof. Hart discusses the significant burden that ulcerative colitis places on patients both clinically and psychosocially, which should be proactively managed as part of a patient-centred care approach to improve overall quality of life.1/3 Next Interview
Dr Melmed discusses why a timely diagnosis and early treatment in ulcerative colitis is so important including the potentially progressive nature of the disease, prognostic risk factors, current treatments for moderate-to-severe vs mild ulcerative colitis, and therapeutic drug monitoring as a useful approach for optimal management.2/3 Next Interview
Prof. Feagan discusses the primary considerations for the development of new therapies for the treatment of moderate-to-severe ulcerative colitis, and the emerging drug classes/therapeutic targets showing greatest potential. He shares his expert insight on how the changing treatment landscape may impact clinical practice.3/3 Take CE/CME Test
Overview & Learning Objectives
In this activity, three experts consider aspects that are crucial to improving outcomes in patients with moderate-to-severe ulcerative colitis: the significance of disease burden when assessing patients; the importance of timely diagnosis and early treatment; and the potential of emerging treatment options.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of immunologists and gastroenterologists involved in the management of ulcerative colitis.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Prof. Ailsa Hart discloses: Advisory board or panel fees from AbbVie, Bristol Myers Squibb, Dr Falk Pharma, Janssen, Merck Sharp & Dohme, Pfizer, Roche and Takeda.
Dr Gil Melmed discloses: Consultancy fees from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Ferring, Janssen, Medtronic, Oshi, Pfizer, Samsung Bioepis, Shield Therapeutics, Takeda and Techlab; Grants/research support from Pfizer; Other financial or material support (royalties, patent, etc.) from Aytu Biosciences; and Stocks/shares (self-managed) from Nephroceuticals.
Prof. Brian Feagan discloses: Advisory board or panel fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, EcoR1 Capital, Genentech/Roche, GlaxoSmithKline, InDex Pharmaceuticals, Janssen, Morphic Therapeutic, Novartis, Origo BioPharma, Pfizer, Progenity, Prometheus, Takeda, Teva and Tillotts Pharma; Consultancy fees from AbbVie, AdMIRx, AgomAb Therapeutics, Akebia Therapeutics, Alimentive Inc., Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc., Arena Pharma, Avir, Azora Therapeutics, Boehringer Ingelheim, Celgene/BMS, Connect BioPharma, Cytoki, Everest Clinical Research Corp., Eli Lilly, Ferring, Galapagos, Galen Pharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Gossamer Pharma, Hoffmann-La Roche, InDex Pharmaceuticals, Intact Therapeutics, Janssen, Kaleido Biosciences, Millennium, Morphic Therapeutics, Mylan, Origo BioPharma, Pandion Therapeutics, Pfizer, Progenity, Prometheus Therapeutics and Diagnostics, PTM Therapeutics, Rebiotix, RedHill Biopharma, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc., Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts Pharma, UCB Pharma, VHsquared Ltd, Viatris, Ysios and Zealand Pharma; Speaker bureau fees from AbbVie, Janssen and Takeda; and Stocks/shares (self-managed) from Gossamer Pharma.
Patrick Brady, MD, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Christina Mackins-Crabtree has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 13 April 2022. Date credits expire: 13 April 2023.
If you have any questions regarding credit please contact email@example.com
After watching this activity, participants should be better able to:
- Describe the disease burden associated with ulcerative colitis and how it relates to patient management
- Recognize the importance of early diagnosis and describe treatment options in patients with moderate-to-severe ulcerative colitis
- Evaluate novel agents in development for the treatment of moderate-to-severe ulcerative colitis and consider how they may impact current clinical practice